When combined with checkpoint blocking drug PD-1 antibody, the vaccines could effectively enhance the activity and proliferation of CD8+ cytotoxic T cells (CTLs), effectively recognizing and eliminating melanoma cells. This evidence concerns the gene PDCD1 and melanoma.